8-K: Cocrystal Pharma Secures $5M Private Placement from OPKO Health

Cocrystal Pharma announced a $5 million private placement with existing investor OPKO Health, Inc., to advance its antiviral drug candidate programs.

Summary

• Cocrystal Pharma, Inc. (Cocrystal) entered into a Securities Purchase Agreement (SPA) with OPKO Health, Inc. (Purchaser) on July 31, 2026.
• Cocrystal sold 5,474,053 shares of its common stock to OPKO Health at $0.9134 per share, raising gross proceeds of $5.0 million.
• The purchase price was based on the Nasdaq Consolidated Bid Price on the trading day of closing.
• Dr. Phillip Frost, Chairman and CEO of OPKO Health, is also a co-founder, director, and principal stockholder of Cocrystal.
• Net proceeds will be used for advancing preclinical and clinical drug candidate programs, and for general corporate purposes and working capital.
• The sale was exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D.
• Cocrystal expects to report topline data from its Phase 1b norovirus trial by the end of Q4 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating continued support from a key investor and progress in drug development, though the capital raise is at a discount.

Positives

• Secured $5 million in gross proceeds through a private placement.
• Received continued investment from a long-time and significant investor, OPKO Health, Inc.
• The investment reflects confidence from OPKO Health in Cocrystal's science and lead asset, CDI-988.
• Proceeds will fund the advancement of preclinical and clinical drug candidate programs.
• No warrants or other derivative securities were included in the transaction, avoiding dilution from such instruments.
• Progressing towards reporting topline data for the Phase 1b norovirus trial by the end of Q4 2026.

Negatives

• The shares were sold at $0.9134 per share, which is the Nasdaq Consolidated Bid Price on the trading day of closing, potentially indicating a discount to market price if the bid price was lower than the prevailing market price.
• The sale of equity was conducted via a private placement, meaning the shares are unregistered and subject to resale restrictions.

Risks

• Potential for adverse findings in the Phase 1b clinical trial for norovirus.
• Risks associated with the development of future preclinical and clinical trials.
• Uncertainty in obtaining regulatory approvals for drug candidates.
• Potential for mutations in targeted viruses to result in resistant variants.
• Competition from other companies developing effective treatments and/or vaccines.
• General risks associated with clinical trials, including potential adverse events.
• Liquidity and ability to raise necessary capital on acceptable terms or at all.
• Risks and uncertainties arising from inflation, affordability, recession, interest rate changes, geopolitical conflicts, and supply chain disruptions.

Future Outlook

Cocrystal Pharma expects to report topline data from its Phase 1b norovirus clinical trial by the end of the fourth quarter of 2026. The company intends to use the net proceeds for the advancement of its preclinical and clinical drug candidate programs, and for general corporate purposes and working capital.

Management Comments

• "OPKOs increased investment reflects the confidence of one of our most steadfast supporters as we approach a defining moment for Cocrystal," said James Sapirstein, Chief Executive Officer of Cocrystal Pharma.
• "We expect to report topline data from our Phase 1b norovirus trial by the end of the fourth quarter of 2026, and were grateful for OPKOs continued conviction in the value of our lead asset, CDI-988, and our broader antiviral pipeline spanning influenza, coronaviruses and hepatitis C."
• "As a longtime investor in Cocrystal, we've watched the Company build a differentiated antiviral platform with real clinical potential," said Dr. Phillip Frost, Chairman and Chief Executive Officer of OPKO Health and co-founder, director and principal stockholder of the Company.
• "This additional investment reflects our continued conviction in Cocrystals science and its path forward."

Industry Context

StockSavvy.ai notes that this private placement highlights the ongoing need for capital in the biotechnology sector, particularly for companies advancing clinical-stage assets. The continued support from a strategic investor like OPKO Health, especially given Dr. Frost's dual role, suggests strong conviction in Cocrystal's specific antiviral programs, particularly its norovirus candidate.

Comparison to Industry Standards

• The private placement was conducted at $0.9134 per share, based on the Nasdaq Consolidated Bid Price. This pricing mechanism is common in private placements but can represent a discount to the prevailing market price, a typical trade-off for securing capital quickly without public market volatility.
• The use of proceeds for advancing preclinical and clinical programs aligns with industry standards for early-stage biotechnology companies seeking to move drug candidates through development pipelines.
• The focus on antiviral therapeutics, specifically norovirus, influenza, coronaviruses, and hepatitis C, targets significant unmet medical needs, a common strategic focus for biopharmaceutical firms.

Related Party Transactions

• The Securities Purchase Agreement was entered into with OPKO Health, Inc. Dr. Phillip Frost, Chairman and Chief Executive Officer of OPKO Health, is also a co-founder, director, and principal stockholder of Cocrystal Pharma, Inc. This represents a related party transaction due to Dr. Frost's significant roles in both entities.

Stakeholder Impact

• Shareholders: The private placement provides capital for continued development, potentially increasing future value, but the sale at the bid price may be viewed as dilutive or at a discount.
• Employees: Continued funding supports ongoing research and development efforts, potentially securing jobs and advancing company goals.
• Creditors: The infusion of working capital can improve the company's ability to meet its financial obligations.
• Management: The successful capital raise and progress in clinical trials are positive indicators for management's strategic execution.

Next Steps

• Advance preclinical and clinical drug candidate programs.
• Report topline data from the Phase 1b norovirus trial by the end of Q4 2026.

Key Dates

Recommendation

The filing details a necessary capital raise to fund ongoing development, supported by a key existing investor. While positive for continued operations, the capital was raised at the bid price, suggesting potential dilution or a discount. The upcoming Phase 1b data for the norovirus program is a critical catalyst, making 'hold' appropriate until those results are known.

Keywords

antiviral therapeutics, norovirus, clinical trial, private placement, drug development, biotechnology, preclinical, Phase 1b